P/E at 37.25 vs Industry's 35.77: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Parity

The current P/E of Sun Pharmaceutical Industries Ltd stands at 37.25, slightly above the Pharmaceuticals & Biotechnology industry average of 35.77. This premium, while not extreme, suggests that the market is pricing in expectations of relatively stronger earnings growth or superior business fundamentals compared to peers. However, the premium is modest enough to warrant a closer look at whether this valuation is justified by recent performance trends or if it signals a stretched price.

Given the sector’s average valuation, Sun Pharma’s premium could reflect its large-cap status and market leadership. Yet, Sun Pharmaceutical Industries Ltd trades at a market capitalisation of ₹4,64,331 crores, underscoring its significant footprint in the sector. Is this valuation premium sustainable given the sector’s competitive pressures? The answer lies partly in the stock’s performance across multiple timeframes.

Performance Across Timeframes: Consistent Outperformance

Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 15.35% return, significantly outperforming the Sensex’s negative 6.73% during the same period. This outperformance extends to shorter timeframes as well, with the stock gaining 16.79% over three months compared to the Sensex’s marginal 0.13% rise. Year-to-date, the stock is up 12.18%, while the Sensex has declined by 9.71%.

Such consistent gains across short and medium terms indicate strong momentum. The stock’s one-month return of 6.75% also surpasses the sector’s average, reflecting resilience amid broader market volatility. However, the stock has experienced a minor pullback in the last two days, losing 0.2%, which is in line with the sector’s performance. What factors might explain this recent short-term weakness despite the longer-term strength? This question is crucial for understanding the stock’s near-term trajectory.

Moving Average Configuration: Bullish Momentum Confirmed

Technically, Sun Pharmaceutical Industries Ltd is trading above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This configuration typically signals strong bullish momentum and a positive trend across both short and long-term horizons.

Being above the 200-day moving average is particularly significant as it often represents a long-term support level. The stock’s proximity to its 52-week high, just 0.97% away, further reinforces this strength. However, the recent two-day consecutive fall and a day change of -0.31% suggest some short-term profit-taking or consolidation. Is this a temporary pause or a signal of a deeper correction ahead? The moving average alignment currently favours the former, but vigilance is warranted.

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has shown mixed results recently, with some stocks posting gains while others remain flat or negative. Sun Pharmaceutical Industries Ltd stands out as one of the sector’s stronger performers, consistently outperforming the Sensex and many peers across multiple timeframes.

This relative strength is notable given the sector’s competitive landscape and regulatory challenges. The stock’s ability to maintain a valuation premium while delivering solid returns suggests it is viewed as a leader within the sector. How sustainable is this leadership in the face of evolving sector dynamics? The answer will depend on ongoing operational performance and market conditions.

Rating Reassessment: Previously Hold, Now Updated

On 8 June 2026, Sun Pharmaceutical Industries Ltd had its rating updated from a previous Hold, according to MarketsMOJO data. While the current rating is not disclosed, this reassessment reflects a significant shift in the company’s evaluation based on recent data and performance metrics.

The previous Hold rating was likely influenced by valuation concerns and sector headwinds. However, the stock’s sustained outperformance, strong moving average positioning, and modest valuation premium have contributed to a revised view. What is the current rating, and how should investors interpret this change? This remains a key question for market participants.

Long-Term Performance: A Mixed Decade

Examining longer-term returns, Sun Pharmaceutical Industries Ltd has delivered a 79.37% return over three years and an impressive 182.47% over five years, both substantially outperforming the Sensex’s 17.37% and 45.81% respectively. However, the 10-year return of 147.89% trails the Sensex’s 176.63%, indicating some periods of underperformance in the more distant past.

This long-term data suggests that while the company has been a strong performer in recent years, it has faced challenges over the last decade that tempered its gains relative to the broader market. Does this historical context affect the current valuation premium and rating reassessment? It is an important consideration for investors weighing the stock’s prospects.

Conclusion: Data Reveals a Stock with Strong Momentum and a Modest Valuation Premium

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical leader trading at a slight premium to its sector. Its consistent outperformance across short, medium, and long-term horizons, combined with a bullish moving average configuration, supports the notion of sustained momentum.

However, the modest valuation premium and recent minor pullbacks highlight the need for careful monitoring. The rating update from a previous Hold reflects this nuanced view, balancing valuation with performance. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today